{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:57:03Z","timestamp":1791669423918,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epigenetic modifications play crucial roles in glioblastoma growth and aggressiveness, with key regulators including histone deacetylases (HDACs), histone acetyltransferases (HATs), and methyltransferases. Targeting these epigenetic alterations has emerged as a promising therapeutic strategy, utilizing DNA methyltransferase (DNMT) inhibitors, HDAC inhibitors (HDACis), and miRNA-based therapies. HDACis, whose effect on p53, p21, Bax, and Bcl-2, have gained significant interest because of their ability to restore the expression of tumor suppressor genes, thereby inducing apoptosis and overcoming therapeutic resistance. Our study demonstrated that a novel hydroxamic acid analogue, compound 3B, effectively inhibited glioma cell (C6) proliferation and exhibited potent anticancer activity. Compound 3B induced G2\/M phase cell cycle arrest, increased apoptotic cell populations, and significantly reduced colony formating efficiency. Confocal imaging revealed nuclear condensation and elevated reactive oxygen species (ROS) levels, indicating oxidative stress. Western blot analysis confirmed that HDAC inhibition increased AcH3K9 protein levels. Further, studies in in vivo xenograft model and allograft C6 Wistar rat model revealed strong antitumour activity, suggesting that compound 3B is a promising therapeutic candidate for glioblastoma treatment.<\/jats:p>","DOI":"10.1186\/s40478-025-02194-7","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:16:24Z","timestamp":1764699384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting glioblastoma with HDAC inhibitors: insights into hydroxamic acid-based therapeutic strategies"],"prefix":"10.1186","volume":"14","author":[{"given":"Padmini","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashaswini","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu Santhi","family":"Venkidesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Madalageri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeresh","family":"Sadashivanavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karkala Sreedhara Ranganath","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Oruganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa Gangadhar","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapaettu","family":"Satyamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-9353","authenticated-orcid":false,"given":"Babitha Kampa","family":"Sundara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2194_CR1","first-page":"1","volume":"10","author":"SHS Alanazi","year":"2024","unstructured":"Alanazi SHS, Khan MF, Alazami AM, Baabbad A, Wadaan MA (2024) Calotropis procera: a double-edged sword against glioblastoma, inhibiting glioblastoma cell line growth by targeting histone deacetylases (HDAC) and angiogenesis. Heliyon 10:1\u201315","journal-title":"Heliyon"},{"key":"2194_CR2","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/brainsci13111536","volume":"13","author":"RS Angom","year":"2023","unstructured":"Angom RS, Nakka NMR, Bhattacharya S (2023) Advances in glioblastoma therapy: an update on current approaches. Brain Sci 13:1536","journal-title":"Brain Sci"},{"key":"2194_CR3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1039\/b703830p","volume":"3","author":"AV Bieliauskas","year":"2008","unstructured":"Bieliauskas AV, Pflum MKH (2008) Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 3:1402\u20131413","journal-title":"Chem Soc Rev"},{"key":"2194_CR4","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.7150\/ijbs.45505","volume":"16","author":"B Buyandelger","year":"2020","unstructured":"Buyandelger B, Bar EE, Hung KS, Chen RM, Chiang YH, Liou JP, Wang JY (2020) Histone deacetylase inhibitor MPT0B291 suppresses glioma growth in vitro and in vivo partially through acetylation of p53. Int J Biol Sci 16:3184\u20133199","journal-title":"Int J Biol Sci"},{"key":"2194_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S et al (2019) Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Therapy 4:62\u201376","journal-title":"Signal Transduct Target Therapy"},{"key":"2194_CR6","doi-asserted-by":"publisher","first-page":"154481","DOI":"10.1016\/j.prp.2023.154481","volume":"246","author":"Z Cheng","year":"2023","unstructured":"Cheng Z, Li S, Yuan J, Li Y, Cheng S, Huang S, Dong J (2023) HDAC1 mediates epithelial\u2013mesenchymal transition and promotes cancer cell invasion in glioblastoma. Pathol Res Pract 246:154481","journal-title":"Pathol Res Pract"},{"key":"2194_CR7","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1038\/cddis.2014.412","volume":"5","author":"M Cornago","year":"2014","unstructured":"Cornago M, Garcia-Alberich C, Blasco-Angulo N, Vall-Llaura N, Nager M, Herreros J, Llovera M (2014) Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis 5:e1435\u2013e1435","journal-title":"Cell Death Dis"},{"key":"2194_CR8","doi-asserted-by":"publisher","first-page":"11523","DOI":"10.1007\/s13277-014-2358-2","volume":"35","author":"J Fan","year":"2014","unstructured":"Fan J, Lou B, Chen W, Zhang J, Lin S, Lv FF, Chen Y (2014) Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumor Biol 35:11523\u201311532","journal-title":"Tumor Biol"},{"key":"2194_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2024.150847","volume":"736","author":"AL Ferreira","year":"2024","unstructured":"Ferreira AL, Menezes A, Sandim V, de Queiroz Monteiro R, Nogueira FCS, Evaristo JAM, de Abreu Pereira D, Carneiro K (2024) Histone deacetylase inhibition disrupts the molecular signature of the glioblastoma secretome related to extracellular vesicle-associated proteins and targets RAB7a and RAB14 in vitro. Biochem Biophys Res Commun 736:1\u201316","journal-title":"Biochem Biophys Res Commun"},{"key":"2194_CR10","first-page":"1","volume":"43","author":"A Gopinathan","year":"2024","unstructured":"Gopinathan A, Sankhe R, Rathi E, Kodi T, Upadhya R, Pai KSR, Kishore A (2024) An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma. J Biomol Struct Dyn 43:1\u201314","journal-title":"J Biomol Struct Dyn"},{"key":"2194_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature07925","volume":"459","author":"JS Guan","year":"2009","unstructured":"Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J et al (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:55\u201360","journal-title":"Nature"},{"key":"2194_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","volume":"13","author":"D Hanisch","year":"2022","unstructured":"Hanisch D, Krumm A, Diehl T, Stork CM, Dejung M, Butter F, Roos WP (2022) Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. Cell Death Dis 13:293\u2013334","journal-title":"Cell Death Dis"},{"key":"2194_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ebiom.2018.05.014","volume":"32","author":"E Hervouet","year":"2018","unstructured":"Hervouet E (2018) The promising role of new generation HDACis in anti-cancer therapies. EBioMedicine 32:6\u20137","journal-title":"EBioMedicine"},{"key":"2194_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1186\/s12885-016-2807-y","volume":"16","author":"I Hrgovic","year":"2016","unstructured":"Hrgovic I, Doll M, Kleemann J, Wang XF, Zoeller N, Pinter A et al (2016) The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer 16:763\u2013784","journal-title":"BMC Cancer"},{"issue":"13","key":"2194_CR15","doi-asserted-by":"publisher","first-page":"9314","DOI":"10.1039\/D4RA00050A","volume":"14","author":"X Jiang","year":"2024","unstructured":"Jiang X, Yan Y, Yang H, Cheng M, Dou D, Liu Y (2024) Design, synthesis and activity evaluation of arctigenin derivatives with HDAC inhibition activity. RSC Adv 14(13):9314\u20139325","journal-title":"RSC Adv"},{"key":"2194_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/jcp.29882","volume":"236","author":"DW Kang","year":"2021","unstructured":"Kang DW, Hwang WC, Noh YN, Kang Y, Jang Y, Kim JA, Min DS (2021) Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. J Cell Physiol 236:549\u2013560","journal-title":"J Cell Physiol"},{"key":"2194_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes14091787","volume":"14","author":"S Kotian","year":"2023","unstructured":"Kotian S, Carnes RM, Stern JL (2023) Enhancing transcriptional reprogramming of mesenchymal glioblastoma with grainyhead-like 2 and HDAC inhibitors leads to apoptosis and cell-cycle dysregulation. Genes 14:1\u201315","journal-title":"Genes"},{"key":"2194_CR18","doi-asserted-by":"publisher","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","volume":"288","author":"BE Lauffer","year":"2013","unstructured":"Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Steiner P (2013) Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem 288:26926\u201326943","journal-title":"J Biol Chem"},{"key":"2194_CR19","first-page":"615","volume":"35","author":"P Lee","year":"2015","unstructured":"Lee P, Murphy B, Miller R, Menon V, Banik NL, Giglio P, Lindhorst SM, Varma AK, Vandergrift WA, Patel SJ, Das A (2015) Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. PubMed 35:615\u2013625","journal-title":"PubMed"},{"key":"2194_CR20","unstructured":"Mikael M (2024) Mocetinostat as a novel selective histone deacetylase (HDAC) inhibitor in the promotion of apoptosis in glioblastoma cell line C6 and T98G. Res Square 1\u201324"},{"key":"2194_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38\u201351","journal-title":"Nat Rev Cancer"},{"key":"2194_CR22","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/jcc.27111","volume":"44","author":"H Mishima","year":"2023","unstructured":"Mishima H, Itoh Y, Kurohara T, Suzuki T, Asada N, Kusakabe KI, Okamoto Y (2023) Origin of the kinetic HDAC2-selectivity of an HDAC inhibitor. J Comput Chem 44:1604\u20131609","journal-title":"J Comput Chem"},{"key":"2194_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1021\/acsmedchemlett.1c00702","volume":"13","author":"C Moreno-Yruela","year":"2022","unstructured":"Moreno-Yruela C, Olsen CA (2022) Determination of slow-binding HDAC inhibitor potency and subclass selectivity. ACS Med Chem Lett 13:779\u2013785","journal-title":"ACS Med Chem Lett"},{"key":"2194_CR24","doi-asserted-by":"crossref","unstructured":"Pai P, Reddy Y, Das I, Venkidesh BS, Bhandari P, Rao P, Sundara BK (2025) Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: insights from in vitro and in vivo studies. Investig New Drugs 43:780\u2013791","DOI":"10.1007\/s10637-025-01559-y"},{"key":"2194_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.chembiol.2022.03.002","volume":"29","author":"NC Payne","year":"2022","unstructured":"Payne NC, Mazitschek R (2022) Resolving the deceptive isoform and complex selectivity of HDAC1\/2 inhibitors. Cell Chem Biol 29:1140\u20131152","journal-title":"Cell Chem Biol"},{"key":"2194_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.phrs.2021.105695","volume":"170","author":"MG Shetty","year":"2021","unstructured":"Shetty MG, Pai P, Deaver RE, Satyamoorthy K, Babitha KS (2021) Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res 170:38\u201351","journal-title":"Pharmacol Res"},{"key":"2194_CR27","doi-asserted-by":"publisher","first-page":"10462","DOI":"10.1038\/s41598-020-67112-4","volume":"10","author":"Y Sixto-L\u00f3pez","year":"2020","unstructured":"Sixto-L\u00f3pez Y, G\u00f3mez-Vidal JA, de Pedro N, Bello M, Rosales-Hern\u00e1ndez MC, Correa-Basurto J (2020) Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines. Sci Rep 10:10462","journal-title":"Sci Rep"},{"key":"2194_CR28","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3390\/biomedicines12112631","volume":"12","author":"F Spallotta","year":"2024","unstructured":"Spallotta F, Illi B (2024) The role of HDAC6 in glioblastoma multiforme: A new avenue to therapeutic interventions? Biomedicines 12:2631","journal-title":"Biomedicines"},{"key":"2194_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm3890","volume":"15","author":"P Tessarz","year":"2014","unstructured":"Tessarz P, Kouzarides T (2014) Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol 15:703\u2013708","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2194_CR30","doi-asserted-by":"publisher","first-page":"15064","DOI":"10.1073\/pnas.0404603101","volume":"101","author":"A Vannini","year":"2004","unstructured":"Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D et al (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci 101:15064\u201315069","journal-title":"Proc Natl Acad Sci"},{"key":"2194_CR31","first-page":"1","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Shi L, Wang Z (2021) A novel hydroxamic acid-based curcumin derivative as potent histone deacetylase inhibitor for the treatment of glioblastoma. Front Oncol 11:1\u201311","journal-title":"Front Oncol"},{"key":"2194_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.001","volume":"379","author":"Z Wang","year":"2016","unstructured":"Wang Z, Hu P, Tang F, Lian H, Chen X, Zhang Y et al (2016) HDAC6 promotes cell proliferation and confers resistance to Temozolomide in glioblastoma. Cancer Lett 379:134\u2013142","journal-title":"Cancer Lett"},{"key":"2194_CR33","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.18632\/oncotarget.3223","volume":"6","author":"R Yang","year":"2015","unstructured":"Yang R, Wu Y, Wang M, Sun Z, Zou J, Zhang Y, Cui H (2015) HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation. Oncotarget 6:7644\u20137656","journal-title":"Oncotarget"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02194-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:39:45Z","timestamp":1767710385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-025-02194-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2194"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02194-7","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Babitha Kampa Sundara, Kapaettu Satyamoorthy, Manasa Gangadhar Shetty, Padmini Pai, and Srinivas Oruganti has patent #202441019540 pending to Manipal Academy of Higher Education. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}